Clinical profile and outcomes of neovascular glaucoma in the era of anti-vascular endothelial growth factor

• Main Authors: Vishwesh Sirish Malgi, Lisika Gawas, Archana Suresh Iyer, Aparna Rao
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2021-01-01
• Series: Indian Journal of Ophthalmology
• Subjects: anti-vegf; blindness; neovascular glaucoma; rubeotic glaucoma; secondary glaucoma
• Online Access: http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=10;spage=2728;epage=2733;aulast=
• ISSN: 0301-4738; 1998-3689

Purpose: To report the clinical profile and visual impairment in various stages of neovascular glaucoma (NVG) at a tertiary eye center in East India. Methods: The electronic medical records of the hospital database of patients with neovascular glaucoma seen between 2013 and 2020 were reviewed. Gonioscopic details were used to stratify patients into nonspecified NVG (Group 1), open-angle NVG (Group 2), and closed-angle NVG (Group 3). The clinical profile, angle features, cause of NVG, systemic associations, visual impairment, and blindness (defined as logarithm of the minimum angle of resolution, LogMar >1.3 at baseline and at final follow-up), and outcomes of medical/surgical interventions were compared between the three groups. Results: Of 846 eyes of 810 patients with NVG (Group 1, n = 564 eyes, Group 2, n = 61 eyes, and Group 3, n = 220 eyes), at baseline, the blindness rates in Groups 3 and 2 were 90 and 75%, respectively. The time from a previous intervention to the onset of NVG ranged from 3 to 5 months, while the median duration of NVG was about 4–4.5 months (0.03–120 months). Multivariate regression identified a longer duration of NVG as the only variable associated with poor final visual acuity. Conclusion: Visual morbidity by NVG remains as high as 75–90% in developing countries, even with the availability of anti-VEGFs and after improved management/investigative at all stages.